Flunitrazepam: A Long-Acting Agent
This medicinal product is characterized by a pronounced and prolonged effect. Its primary role is to increase sleep depth.
Pharmacokinetic Features:
- Onset of action: therapeutic effects develop within 20–45 minutes after administration.
- Duration: persists for 6–8 hours.
- Metabolism and excretion: the drug is metabolized in the liver and excreted predominantly by the kidneys. The elimination half-life ($t_{1/2}$) is a substantial 24–36 hours, resulting in prolonged persistence of the substance in the body.
The safety profile of flunitrazepam shares many similarities with nitrazepam, but requires strict adherence to contraindications. The drug must not be prescribed for liver or kidney impairment, myasthenia gravis, or during pregnancy and lactation. Special attention should be paid to drug interactions: flunitrazepam is strictly not recommended for use in combination with monoamine oxidase inhibitors (MAOIs).
Short-Acting Agents: Triazolam
Unlike long-acting benzodiazepines, drugs in this group possess a short elimination half-life, which alters their clinical profile.
Triazolam is characterized by a half-life ($t_{1/2}$) of only 1–5 hours.
Key Advantages:
- Virtually no risk of drug accumulation (cumulation) with repeated dosing.
- Significantly less pronounced residual next-day effects (often called a "hangover" effect) compared to long-acting benzodiazepines.
Midazolam: From Insomnia to Anesthesia
Midazolam is also classified as a short-acting benzodiazepine with an elimination half-life ($t_{1/2}$) of 1 to 5 hours. Its administration route and clinical application are strictly differentiated based on the therapeutic goal.
Use as a Hypnotic (per os): Oral administration is primarily prescribed to facilitate sleep onset. As with triazolam, there is no drug accumulation and only minimal residual next-day effects.
Use in Anesthesiology:
- Premedication: used before surgical procedures (administered orally or intramuscularly).
- Induction of anesthesia: administered via the intravenous route.
Risk Warning: Parenteral (intravenous) use of midazolam carries serious risks. Rapid intravenous injection can cause severe respiratory depression, potentially leading to complete apnea.